The quarter and the reporting basis
Corteva released results on November 11 for the third quarter ended September 30, 2026. In the company’s pro forma presentation, net sales were $1.591 billion, compared with $1.742 billion a year earlier, a decline of 9%. The after-tax loss from continuing operations was $54 million, versus income of $60 million.
Adjusted pro forma operating EBITDA was $222 million, down 17%. That is a non-GAAP measure and is separate from the after-tax continuing-operations result; it is not a cash-flow or net-profit figure.
Where the pressure was concentrated
Corteva attributed weaker conditions in Brazil to purchasing delays, financing constraints and pricing pressure on mature products. Latin America organic sales fell 31%, while North America organic sales rose 7%. The company also cited pressure on US acetochlor pricing.
These are regional and product-market observations from the issuer. The results do not establish that every product or every customer faced the same price change.
The updated full-year ranges
Corteva now expects 2026 adjusted pro forma operating EBITDA of $1.1 billion to $1.125 billion and adjusted pro forma operating EPS of $0.76 to $0.80. The release describes these as forecasts and says it cannot provide a forward-looking reconciliation to the closest GAAP measures without unreasonable effort.
The company scheduled its results webcast for November 12 at 10:30am Eastern, or 15:30 UTC. The linked release points to the official investor presentation page. That scheduled discussion is separate from the quarter already reported; the outlook is not a guarantee of annual results.
